Anti-TGF beta Receptor II antibody [MM0056-4F14] - BSA and Azide free

• IHC-P

Unknown

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-TGF beta Receptor II antibody [MM0056-4F14] - BSA and Azide free (AB78419)

ab78419 at 1/200 dilution, staining TGF beta Receptor II in human placental tissue section by Immunohistochemistry (Formalin/PFA fixed paraffin-embedded sections).

• Flow Cyt

Unknown

Flow Cytometry - Anti-TGF beta Receptor II antibody [MM0056-4F14] - BSA and Azide free (AB78419)

Overlay histogram showing HepG2 cells stained with ab78419 (red line). The cells were fixed with 80% methanol (5 min) and incubated in 1x PBS / 10% normal goat serum / 0.3M glycine to block non-specific protein-protein interactions. The cells were then incubated with the antibody (ab78419, 1μg/1x10⁶ cells) for 30 min at 22°C. The secondary antibody used was DyLight® 488 goat anti-mouse IgG (H+L) (ab96879) at 1/500 dilution for 30 min at 22°C. Isotype control antibody (black line) was mouse IgG1 [ICIGG1] (ab91353, 2μg/1x10⁶ cells) used under the same conditions. Acquisition of >5,000 events was performed.
Please note that Abcam do not have any data for use of this antibody on non-fixed cells. We welcome any customer feedback.

• IHC

CiteAb

Immunohistochemistry - Anti-TGF beta Receptor II antibody [MM0056-4F14] - BSA and Azide free (AB78419)

Immunohistochemistry using Anti-TGF beta Receptor II antibody [MM0056-4F14] - BSA and Azide free, ab78419. Publication image from Eckmann, L. et al., 2015, Mol Cancer, 26497569. Legend direct from paper.

Loss of nuclear p21 is indicative of activin/pAkt activation, while nuclear p21 is associated with TGFβ/pERK activation in primary colon cancer tissues. In human colon cancer tissue, loss of nuclear p21 is associated with ACVR2A/pAkt expression while nuclear p21 is associated with TGFBR2/pERK expression. A total of 110 primary human colon cancer tissues were stained for ACVR2A/TGFBR2/p21/pERK/pAkt expression and pathway expression associations were determined. a Representative colon cancer tissues showing nuclear (p21/pERK) or cytosolic (TGFBR2/ACVR2A/pAkt) expression (upper panel) versus loss (lower panel). b Schematic of colon cancer signaling pathways based on signal component staining. Dominant pathways with p21 expression as diverging point drawn in red (p21 loss/ACVR2A+/pAkt + and p21 expression/TGFBR2+/pERK+, respectively). For statistical analysis, see Table 1